Access cutting-edge cystic fibrosis treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access cystic fibrosis specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related cystic fibrosis treatment provided free
The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Sponsor: Vertex Pharmaceuticals Incorporated
Check if you qualify for this cystic fibrosis clinical trial in Chicago, IL
If you're searching for cystic fibrosis treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cystic fibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.